Julien Santo

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

Séverine Vermeire, Bruce E. Sands, Herbert Tilg et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 64 citations

Medicine, Clinical Sciences, Pharmacology +14

Cochlear stem/progenitor cells from a postnatal cochlea respond to Jagged1 and demonstrate that notch signaling promotes sphere formation and sensory potential

Etienne Savary, Jean Charles Sabourin, Julien Santo et al. · Mechanisms of Development · 2008 · 46 citations

Life Sciences, Developmental Biology, Neuroscience +14

Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study

C. Daïen, Marek Krogulec, Paul Gineste et al. · Annals of the Rheumatic Diseases · 2022 · 32 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases

Cécile Apolit, Noëlie Campos, Audrey Vautrin et al. · Clinical and Translational Gastroenterology · 2022 · 29 citations · Full text

Veterinary Medicine, Immunology, Molecular Medicine +17

Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study

Séverine Vermeire, Josianne Nitcheu, Paul Gineste et al. · Journal of Crohn s and Colitis · 2025 · 11 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +13